Specifically, the lack of approved HER2-targeted therapies for non-NSCLC with ERBB2 mutations in the absence of amplification/overexpression suggests an unmet clinical need for a substantial population of patients (10, 11). Here, ERBB2 is linked to non-small cell lung carcinoma.